Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Revumenib and Venetoclax for the Treatment of Patients with Acute Myeloid Leukemia with Measurable Residual Disease

Trial Status: active

This phase I/II trial tests the safety, tolerability, best dose, and effectiveness of revumenib when given together with venetoclax for treating patients with acute myeloid leukemia (AML) with measurable residual disease. Revumenib is in a class of medications called protein-protein interaction inhibitors. It may stop the survival, growth, transformation, and proliferation of certain kinds of leukemia cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving revumenib and venetoclax together may help to control measurable residual disease-positive AML